A Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non- Small Cell Lung Cancer After Osimertinib Failure
Public ClinicalTrials.gov record NCT04988295. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Open-Label, Randomized Study of Amivantamab and Lazertinib in Combination With Platinum-Based Chemotherapy Compared With Platinum-Based Chemotherapy in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer After Osimertinib Failure
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to assess the efficacy of adding lazertinib to amivantamab, carboplatin, and pemetrexed (LACP/ACP-L dosing strategies) and amivantamab, carboplatin and pemetrexed (ACP) compared with carboplatin and pemetrexed (CP) in participants with locally advanced or metastatic epidermal growth factor receptor (EGFR) Exon 19del or Exon 21 L858R substitution non-small cell lung cancer (NSCLC) after osimertinib failure. The purpose of the extension cohort is to further describe the safety and efficacy for the ACP-L dosing schedule versus ACP with additional data. After completion of the primary analysis, the study may eventually transition to an open-label extension (OLE) or long-term extension (LTE) phase during which participants will have the option to continue their assigned treatment.
Study identification
- NCT ID
- NCT04988295
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 776 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Nov 17, 2021 (Actual)
- Primary completion
- Jul 10, 2023 (Actual)
- Completion
- Jul 3, 2028 (Estimated)
- Last update posted
- Sep 28, 2026
2021 – 2028
United States locations
- U.S. sites
- 28
- U.S. states
- 17
- U.S. cities
- 26
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Southern Cancer Center, PC | Mobile | Alabama | 36608 | — |
| Arizona Oncology Associates | Tucson | Arizona | 85711 | — |
| City of Hope | Duarte | California | 91010 | — |
| Cedars Sinai Medical Center | Los Angeles | California | 90048 | — |
| University of California Irvine | Orange | California | 92868 | — |
| Rocky Mountain Cancer Centers | Colorado Springs | Colorado | 80907 | — |
| Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center | Fort Lauderdale | Florida | 33308 | — |
| University Cancer And Blood Center LLC | Athens | Georgia | 30607 | — |
| University of Mississippi Medical Center | Jackson | Mississippi | 39216 | — |
| Nebraska Cancer Specialists | Grand Island | Nebraska | 68803 | — |
| Astera Cancer Care | East Brunswick | New Jersey | 08816 | — |
| TriHealth Network | Cincinnati | Ohio | 45220 | — |
| Providence Portland Medical Center | Portland | Oregon | 97213 | — |
| Kaiser Permanente Northwest | Portland | Oregon | 97227 | — |
| Alliance Cancer Specialists | Horsham | Pennsylvania | 19044 | — |
| University of Pittsburgh Medical Center | Pittsburgh | Pennsylvania | 15232 | — |
| Baptist Cancer Center | Memphis | Tennessee | 38120 | — |
| Texas Oncology-Medical City Dallas | Dallas | Texas | 75230 | — |
| Texas Oncology Baylor Charles A Sammons Cancer Center | Dallas | Texas | 75246 | — |
| Texas Oncology | Grapevine | Texas | 76051 | — |
| Oncology Consultants Texas | Houston | Texas | 77030 | — |
| Texas Oncology - Northeast | Longview | Texas | 75601 | — |
| University of Vermont Medical Center | Burlington | Vermont | 05401 | — |
| University of Virginia | Charlottesville | Virginia | 22908 | — |
| Virginia Cancer Specialists | Fairfax | Virginia | 22031 | — |
| Blue Ridge Cancer Care | Wytheville | Virginia | 24382 | — |
| NorthWest Medical Specialties, PLLC | Puyallup | Washington | 98373 | — |
| Compass Oncology | Vancouver | Washington | 98684 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 221 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04988295, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 28, 2026 · Synced Oct 17, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT04988295 live on ClinicalTrials.gov.